Valneva: new positive data for Ixchiq
(CercleFinance.com) - Valneva announces further positive Phase 3 results in adolescents for its single-dose chikungunya vaccine, Ixchiq, demonstrating a seroresponse rate of 98.
3% one year after a single vaccination.
These results support and confirm those previously published in 12-17 year-olds, on which the vaccine company has based its applications for extension of the indication to this age group in the US, Europe and Canada.
The results obtained during this trial should also enable the vaccine to be licensed in Brazil, which would then constitute the first marketing authorisation for use in an endemic population.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
3% one year after a single vaccination.
These results support and confirm those previously published in 12-17 year-olds, on which the vaccine company has based its applications for extension of the indication to this age group in the US, Europe and Canada.
The results obtained during this trial should also enable the vaccine to be licensed in Brazil, which would then constitute the first marketing authorisation for use in an endemic population.
Copyright (c) 2025 CercleFinance.com. All rights reserved.